България - български - БАБХ (Българска агенция по безопасност на храните)

kepro b.v. - Толтразурил - перорален разтвор - 25 mg/ml - пилета, пуйки

България - български - БАБХ (Българска агенция по безопасност на храните)

ФАРМА ВЕТ ООД - sulfachlorpyrazin-натрий монохидрат - перорален прах - 30 g/100 g - агнета, зайци, кокошки, пилета, пуйки, телета, ярета

България - български - БАБХ (Българска агенция по безопасност на храните)

СУДАХИМ ЕООД - sulfachlorpyrazin натрий - прах за прилагане във вода за пиене - мин. 99.0 g/100 g - агнета, зайци, птици, пуйки, ярета

Европейски съюз - български - EMA (European Medicines Agency)

theratechnologies europe limited - ibalizumab - ХИВ инфекции - Антивирусни средства за системно приложение - trogarzo, в комбинация с други антиретровирусными(и), показан за лечение на възрастни пациенти с множествена лекарствена резистентност на ХИВ-1 инфекция, за когото това е друг начин, не е възможно да се изгради супрессивная противовирусная схема.

България - български - БАБХ (Българска агенция по безопасност на храните)

huvepharma sa - Ампролиум - разтвор за прилагане във вода за пиене - 400 mg/ml - кокошки, пуйки

Европейски съюз - български - EMA (European Medicines Agency)

novartis europharm limited - inclisiran - hypercholesterolemia; dyslipidemias - Липидни модифициращи агенти - leqvio is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:in combination with a statin or statin with other lipid-lowering therapies in patients unable to reach ldl-c goals with the maximum tolerated dose of a statin, oralone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.

България - български - БАБХ (Българска агенция по безопасност на храните)

sp veterinaria sa - Ампролиум - разтвор за прилагане във водата за пиене - 400 mg/ml - пилета, пуйки

България - български - БАБХ (Българска агенция по безопасност на храните)

v.m.d.n.v. - Ампролиум - разтвор за прилагане във водата за пиене - 400 mg/ml - патици, пилета, пуйки

Европейски съюз - български - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - sitagliptin fumarate - Захарен диабет тип 2 - Лекарства, използвани при диабет - for adult patients with type 2 diabetes mellitus, sitagliptin sun is indicated to improve glycaemic control:as monotherapy:- in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. as dual oral therapy in combination with:- metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control. - a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance. - a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. a thiazolidinedione) when use of a pparγ agonist is appropriate and when diet and exercise plus the pparγ agonist alone do not provide adequate glycaemic control. as triple oral therapy in combination with:- a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. - a pparγ agonist and metformin when use of a pparγ agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. sitagliptin sun is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.

Европейски съюз - български - EMA (European Medicines Agency)

accord healthcare s.l.u. - sitagliptin hydrochloride - Захарен диабет тип 2 - Лекарства, използвани при диабет - for adult patients with type 2 diabetes mellitus, sitagliptin accord is indicated to improve glycaemic control:as monotherapy:- in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. as dual oral therapy in combination with:- metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control. - a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance. - a peroxisome proliferator-activated receptor gamma (ppary) agonist (i. a thiazolidinedione) when use of a ppary agonist is appropriate and when diet and exercise plus the ppary agonist alone do not provide adequate glycaemic control. as triple oral therapy in combination with:- a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. - a ppary agonist and metformin when use of a ppary agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. sitagliptin accord is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.